Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Marquis Who's Who honors Jan M. Lundberg, PhD, for his expertise in pharmaceuticals and research. Dr. Lundberg has over 30 years of professional experience in the pharmaceutical industry.

LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...

Eli Lilly expects to miss its recent revenue estimate for 2024 by about $400 million, according to a preliminary report.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Joe Biden Announces Stimulus Checks for People Impacted by California Fires 14 Rare Animals That Look Too Bizarre to Be Real Meta targeting lowest-performing employees in latest round of layoffs I've ...